3 results
Approved WMOCompleted
To determine the safety and effectiveness of the PROMUS Element* Everolimus-Eluting Coronary Stent System (Boston Scientific Corporation [BSC], Natick, MA) for the treatment of patients with up to 2 de novo atherosclerotic lesions
Approved WMOCompleted
primaryTo evaluate the effect of MEDI6570 on non-calcified coronary atherosclerotic plaques compared with placebosecundaryTo evaluate the effect of MEDI6570 on a surrogate biomarker of HF compared with placeboTo evaluate the effect of MEDI6570 on…
Approved WMOCompleted
To determine whether a potent topical CS is more effective than a mild topical CS in the treatment of children with a moderate flare-up of atopic dermatitis in primary care on short and long term.